Recent Findings Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia
Safety Signal: The data confirmed a known signal for "dysesthesia" (skin sensitivity) in ~21% of patients, a unique side effect of the Triple G mechanism compared to GLP-1 alone
The medication reduces the biological barriers to weight loss while you build the behavioral and lifestyle foundation that will support your new weight long-term
Janus kinase (JAK) inhibitors represent newer targeted synthetic DMARDs with demonstrated efficacy, though they carry boxed warnings regarding serious infections, malignancy, major adverse cardiovascular events, and thrombosis
Diarrhea May be worse after high-fat meals, high-sugar foods, alcohol, or sugar alcohols